申联生物股东减持完成，2025年业绩预亏但亏损收窄

Core Viewpoint - UBI has reduced its stake in Shenglian Bio (600201) by 12,319,240 shares, representing 3% of the total share capital, decreasing its ownership from 10.52% to 7.52% [1] Group 1: Shareholding Changes - UBI's share reduction was executed at a price range of 8.80-9.89 CNY per share, totaling approximately 111 million CNY [1] - The reduction plan commenced on November 13, 2025, and was completed on February 9, 2026, without changing the controlling shareholder or actual controller of the company [1] Group 2: Financial Performance - Shenglian Bio anticipates a net loss of approximately 20 million CNY for 2025, which is a 55% improvement compared to the 2024 loss [1] - The adjusted net loss is expected to be around 23.5 million CNY, reflecting a 51% reduction [1] - The improvement in losses is attributed to cost reduction and efficiency enhancement, despite increased competition in the animal health industry leading to lower product prices and higher accounts receivable impairment losses [1][3] Group 3: Stock Performance - Over the past week (February 5 to 11, 2026), Shenglian Bio's stock price fluctuated by 3.63%, with a high of 9.87 CNY on February 10 and a low of 9.24 CNY on February 6 [2] - Following the completion of the share reduction announcement on February 9, the stock price rose by 3.32% with a trading volume increase (turnover rate of 1.06%) [2] - On February 11, the closing price was 9.71 CNY, reflecting a single-day increase of 1.04% [2]